학술논문
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
13652133